“PO-38 | Impact of Atogepant on Achieving Best Possible Quality of Life Among Patient Global Impression of Change Responders: Cristina Tassorelli,1 Pranav Gandhi,2 Molly Duan,2 Karen Carr,2 Kandavadivu Umashankar,2 Jonathan Stokes,2 Grace Forde,3 Tanya Bilchik,4 Martina Martini*, Rashmi Halker Singh5 | 1University of Pavia, Pavia, Italy; 2AbbVie, North Chicago, IL, USA; 3North American Partners in Pain Management, North New Hyde Park, NY, USA; 4Department of Neurology, Yale School of Medicine, New Haven, CT, USA; 5Mayo Clinic, Phoenix, AZ, USA *Abbvie Srl, Rome, Italy”. 2025. Confinia Cephalalgica 35 (S1). https://doi.org/10.4081/cc.2025.15860.